Epilepsy

New research found over a quarter of children with treatment-refractory epilepsy sustained treatment response to CBD over four years.

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the findings and the importance of discovering more about mechanisms of action.

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the future of epilepsy and shared which studies of the condition that he’s been keeping an eye on.

The director of Pediatric Epilepsy at Centennial Children's Hospital spoke about the need to increase epilepsy's awareness and the clinical development of several agents that he is keeping his eyes on.

Neurology News Network for the week of January 26, 2019.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville discussed when to best perform routine EEG in patients with epilepsy.

The director of the Epilepsy Center at Cleveland Clinic spoke about the use of deep brain stimulation for the treatment of refractory epilepsy, and who the ideal candidate is for implantation.

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.

The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville spoke about how to best identify adult patients in need of routine EEG and what it will bring to the table relative to the clinician.

Neurology News Network for the week of January 19, 2019.

The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.

Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.

The professor and vice chair of the neurology department at UCLA discussed the new VNS, RNS and DBS CPT codes for 2019.

The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.

The treatment was originally branded as Sabril (Lundbeck) and approved in August 2009 as monotherapy for infantile spasms. This generic formulation approval was granted by the agency to Teva Pharmaceuticals.

Liu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.

The attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.

The AAN position statement author further addressed the opposing position of the Nevada law, the AAN’s position on brain death, and what clinicians need to know in regard to determining it.

The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about when clinicians should initiate and stop anti-seizure medications.

Neurology News Network for the week of January 12, 2019.

The Chair of the AAN’s Ethics, Law and Humanities Committee spoke to the American Academy of Neurology’s goal to improve the consistency of determining brain death.

A new research project is underway to improve the pre-surgical evaluation of pediatrics with medical refractory epilepsy.

The section chief of pediatric neurology at Nationwide Children’s Hospital shared his excitement about the approval of Epidiolex and its potential as a therapeutic.

This guide includes everything you need to know about cannabidiol (Epidiolex, GW Pharmaceuticals) for the treatment of 2 rare types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.